Last updated: February 19, 2026
This analysis details key considerations for securing and enforcing biopharmaceutical patents in Indonesia, focusing on patentability requirements, enforceability challenges, and the strategic scope of patent claims. Indonesian patent law, influenced by international treaties, presents specific nuances for the biopharmaceutical sector.
What are the Patentability Requirements for Biopharmaceuticals in Indonesia?
Indonesian patent law, outlined in Law No. 13 of 2016 on Patents, establishes three core criteria for patentability: novelty, inventive step, and industrial applicability [1].
Novelty
A biopharmaceutical invention is considered novel if it has not been previously disclosed anywhere in the world before the filing date of the patent application. This includes disclosures in published patent documents, scientific journals, public use, or sale [1]. For biopharmaceuticals, demonstrating novelty can involve showcasing new molecular entities, novel formulations, new uses of known compounds, or new manufacturing processes.
Inventive Step
An invention possesses an inventive step if it is not obvious to a person skilled in the art, considering the existing state of the art at the time of filing [1]. This requires a significant technical advancement over prior art. In the biopharmaceutical context, this often means demonstrating unexpected results, overcoming technical challenges, or providing a technical effect that was not predictable. For instance, a new drug with significantly improved efficacy or a reduced side effect profile compared to existing treatments would likely satisfy the inventive step requirement.
Industrial Applicability
The invention must be capable of being made or used in any kind of industry [1]. This criterion is generally straightforward for biopharmaceutical products and processes, as they are inherently developed for therapeutic or diagnostic applications within the pharmaceutical industry.
What Specific Exclusions Apply to Biopharmaceutical Patents?
Indonesian Patent Law lists several categories of inventions that are not patentable, some of which are relevant to the biopharmaceutical sector. Article 7 of Law No. 13 of 2016 states that the following are not considered inventions:
- Discoveries, scientific theories, and mathematical methods.
- Living organisms, except for microorganisms.
- Biologically active substances or methods for their production, except for non-living microorganisms [1].
This exclusion for living organisms and biological methods requires careful navigation. However, the exception for non-living microorganisms allows for patent protection of engineered bacteria or yeasts used in producing therapeutic proteins, for example. Inventions related to methods of treatment, diagnostic methods performed on the human or animal body, and new uses of known substances are also excluded from patentability [1].
How are Microorganisms and Biological Processes Treated Under Indonesian Patent Law?
Indonesian patent law differentiates between living organisms and microorganisms. While living organisms are generally excluded, non-living microorganisms are patentable. This typically includes genetically modified microorganisms [1].
Furthermore, methods of producing non-living microorganisms can be patented if they meet the novelty, inventive step, and industrial applicability criteria. However, the methods of treatment using these microorganisms or their products are not patentable.
What are the Key Factors Affecting Patent Enforceability in Indonesia?
Enforcing biopharmaceutical patents in Indonesia involves navigating the legal framework, understanding potential challenges, and utilizing available remedies.
Patent Infringement
Patent infringement occurs when a third party makes, uses, sells, offers for sale, or imports a patented invention without the patent holder's authorization [1]. For biopharmaceutical patents, infringement can manifest in several ways:
- Unauthorized manufacturing or sale of the patented drug substance.
- Marketing of a drug product containing the patented active pharmaceutical ingredient (API).
- Use of a patented manufacturing process for an API or drug product.
- Importation of infringing products.
Procedural Aspects of Enforcement
Patent enforcement in Indonesia typically proceeds through civil litigation. The Commercial Court has exclusive jurisdiction over patent disputes [2].
- Civil Lawsuit: A patent holder can file a civil lawsuit against an alleged infringer seeking remedies such as injunctions and damages.
- Injunctions: Courts can issue preliminary injunctions to prevent further infringement during the legal proceedings or permanent injunctions as part of a final judgment [1].
- Damages: Compensatory damages are awarded to compensate the patent holder for losses incurred due to infringement. Calculating damages can be complex, often involving lost profits or reasonable royalties.
- Criminal Penalties: While civil remedies are primary, the Indonesian Patent Law also provides for criminal sanctions, including imprisonment and fines, for intentional infringement [1].
Challenges in Enforcement
Enforcing biopharmaceutical patents can present specific challenges in Indonesia:
- Burden of Proof: The patent holder bears the burden of proving infringement, which can be difficult, particularly for process patents where the infringing process may not be directly observable. Demonstrating that an allegedly infringing product was made using a patented process often requires access to the infringer's manufacturing information, which can be challenging to obtain.
- Effect of Generic Competition: The presence of generic drug manufacturers is a significant factor. Generic companies may challenge the validity of existing patents or argue non-infringement.
- Compulsory Licensing: Under certain circumstances, particularly for public health emergencies or if a patented invention is not worked (used) in Indonesia after three years from the grant date, the government may issue a compulsory license to a third party [1]. This allows others to use the patented invention upon payment of reasonable remuneration.
- Customs Enforcement: While not a direct court proceeding, patent holders can request customs authorities to seize infringing goods at the border. This requires providing sufficient information to customs regarding the patent and the infringing products [1].
Strategies for Effective Enforcement
- Robust Patent Portfolio: Maintaining a strong portfolio of patents covering the API, formulations, methods of manufacturing, and methods of use can provide multiple layers of protection.
- Early Monitoring: Proactive monitoring of the market for potential infringing products is crucial. This includes tracking new drug approvals and market introductions.
- Clear and Broad Claims: Well-drafted patent claims that clearly define the scope of the invention are essential for successful enforcement.
- Expert Testimony: In complex biopharmaceutical patent cases, expert testimony from scientists and economists is often vital to explain technical aspects and quantify damages.
- Alternative Dispute Resolution (ADR): While litigation is common, parties may consider arbitration or mediation as alternative dispute resolution mechanisms.
How Can Claim Scope Be Strategically Managed for Biopharmaceutical Patents in Indonesia?
The scope of patent claims dictates the extent of exclusive rights granted. Strategic claim drafting is paramount for effective protection of biopharmaceutical innovations.
Types of Claims Relevant to Biopharmaceuticals
Biopharmaceutical patents can include various types of claims:
- Product Claims: These claims cover the active pharmaceutical ingredient (API) itself, such as a specific protein, antibody, or small molecule. They provide the broadest protection but are subject to strict novelty and inventive step requirements.
- Formulation Claims: These claims cover specific compositions or formulations of the API, including excipients, dosage forms (e.g., tablets, injectables), and delivery systems. They can offer protection even if the API itself is off-patent or if a competitor develops a similar API.
- Process Claims: These claims cover methods of manufacturing the API or the final drug product. They are crucial for protecting proprietary manufacturing techniques that might be difficult for competitors to reverse-engineer.
- Method of Use Claims: These claims cover specific therapeutic uses of a known or new compound. Indonesian law excludes methods of treatment of the human or animal body from patentability [1]. Therefore, claims must be carefully crafted to avoid direct treatment methods. For example, claiming a "method for identifying patients who will respond to treatment with compound X" or a "method for manufacturing a medicament for treating disease Y" might be permissible if carefully worded to focus on a non-therapeutic aspect or a pre-treatment diagnostic step, rather than the act of treating.
Strategic Considerations for Claim Drafting
- Breadth vs. Specificity: Claims need to be broad enough to cover potential variations and circumvention strategies by competitors but specific enough to be patentable and clearly distinguishable from prior art.
- Broad Claims: For a novel API, a claim covering the compound itself and its pharmaceutically acceptable salts, solvates, and polymorphs offers extensive protection.
- Specific Claims: Claims directed to specific formulations with particular excipients or concentration ranges can protect against competitors who use slight variations of the API in a different formulation.
- Enabling Disclosure: The patent specification must provide a detailed and enabling description of the invention, allowing a person skilled in the art to make and use the invention without undue experimentation [1]. This is particularly important for complex biopharmaceuticals, such as monoclonal antibodies, where detailed sequence information, production methods, and characterization data are required.
- Claim Dependant Claims: Utilizing a hierarchical claim structure with independent and dependent claims allows for broader coverage initially, with dependent claims providing fallback positions with narrower, more specific protection.
- Addressing Manufacturing Processes: For novel manufacturing processes, claims should focus on the unique steps, reagents, or conditions that impart novelty and an inventive step. This can prevent competitors from using a similar but slightly modified process.
- Navigating Exclusions for Method of Treatment: The exclusion of methods of treatment requires careful drafting. Instead of claiming "a method of treating cancer using drug Z," one might claim "a pharmaceutical composition comprising drug Z for use in treating cancer" or "a method of preparing a medicament for the treatment of cancer comprising [specific manufacturing steps]." The focus shifts from the act of treatment to the product or its preparation.
- Post-Grant Amendments and Divisional Applications: If the initial claims are too broad or lack sufficient support, amendments may be necessary during examination. Divisional applications can be filed from a pending parent application to pursue claims that were originally too broad or to cover different aspects of the invention in separate applications [1].
Case Study Example: Antibody Patents
For antibody therapeutics, claim scope is critical.
- Sequence Claims: Claims can cover the specific amino acid sequences of the antibody's variable regions (e.g., VH, VL) or complementarity-determining regions (CDRs).
- Binding Claims: Claims can define the antibody by its ability to bind to a specific epitope on a target antigen with a certain affinity (e.g., measured by KD or IC50).
- Functional Claims: Claims might also cover the antibody's biological function, such as its ability to block a signaling pathway or elicit a specific cellular response.
- Formulation and Manufacturing Claims: As with other biopharmaceuticals, specific formulations and manufacturing processes for antibodies are patentable and offer additional layers of protection.
The strategy involves securing broad claims covering the antibody itself and its key functional attributes, complemented by narrower claims covering specific formulations, manufacturing methods, and potentially specific therapeutic uses that can be framed to avoid the "method of treatment" exclusion.
Key Takeaways
Indonesian patent law presents a structured framework for biopharmaceutical innovation. Novelty, inventive step, and industrial applicability are foundational patentability requirements. Specific exclusions, particularly for living organisms (except non-living microorganisms) and methods of treatment, necessitate careful claim drafting. Enforceability relies on civil litigation in the Commercial Court, with remedies including injunctions and damages, though challenges exist regarding the burden of proof and potential compulsory licensing. Strategic claim scope management, encompassing product, formulation, process, and carefully framed method of use claims, is crucial for maximizing protection against competitors in the Indonesian market.
FAQs
-
Can a patent be obtained for a newly discovered gene sequence with therapeutic potential in Indonesia?
While naturally occurring gene sequences are generally considered discoveries and thus unpatentable, if the gene sequence is isolated, characterized, and has been engineered or modified to produce a therapeutic product, it may be eligible for patent protection if it meets novelty, inventive step, and industrial applicability criteria. The application would need to demonstrate a specific, industrial use beyond its natural existence.
-
What is the typical duration of patent protection for biopharmaceuticals in Indonesia?
Standard patent protection in Indonesia has a term of 20 years from the filing date of the application, subject to the payment of annual renewal fees [1].
-
How does the Indonesian Patent Office examine biopharmaceutical patent applications?
The Indonesian Patent Office conducts substantive examination to assess whether an application meets the patentability requirements. This process involves prior art searches and technical reviews. For biopharmaceutical inventions, examination often requires specialized technical expertise, and applicants may need to provide detailed biological data, sequence information, and evidence of utility.
-
What recourse does a patent holder have if a competitor launches a generic version of their patented drug before the patent expires, alleging the patent is invalid?
The patent holder can initiate infringement proceedings in the Commercial Court. Simultaneously, the patent holder may need to defend the validity of their patent against challenges raised by the competitor. The court will assess both infringement and validity.
-
Is it possible to protect new formulations of an existing patented drug in Indonesia?
Yes, new formulations of an existing drug can be patentable if they provide a technical advantage, such as improved stability, bioavailability, or reduced side effects, and meet the requirements of novelty and inventive step. Such formulations can be protected by separate patent applications, providing additional market exclusivity.
Citations
[1] Law No. 13 of 2016 on Patents (Undang-Undang Nomor 13 Tahun 2016 tentang Paten).
[2] Law No. 30 of 2000 on Industrial Secrets (Undang-Undang Nomor 30 Tahun 2000 tentang Rahasia Dagang) as amended. (Note: While Law No. 30 of 2000 deals with trade secrets, the jurisdiction for patent disputes is established through procedural laws and regulations governing the Commercial Court, often referencing the Patent Law for substantive issues. For specific procedural details and jurisdiction, reference to the Indonesian Civil Procedure Code and related judicial regulations is also relevant.)
